Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Sintilimab + XELOX in Advanced Gastric Cancer
NCT06094868Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fruquintinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by The Second Affiliated Hospital of Nanchang University. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06094868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094868.